^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TAK-012

    i
    Other names: TAK-012, GDX012, Allogeneic variable delta 1 gamma-delta T cell cancer therapy, allogeneic Vδ1 γδ T cell therapy, GDX 012, TAK 012, GDX-012, TAK012
    Associations

    News

    Trials
    Company:
    Takeda
    Drug class:
    Immunomodulator, γδ TCR modulator
    Related drugs:
    Associations

    News

    Trials
    3ms
    TAK-012-1501: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=14, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | N=53 --> 14 | Trial completion date: Jun 2027 --> May 2026 | Trial primary completion date: Apr 2026 --> Aug 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TAK-012
    over2years
    A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=53, Not yet recruiting, Takeda
    New P1/2 trial
    |
    cyclophosphamide • TAK-012